Jerry S Wolinsky Selected Research

Glatiramer Acetate (Copaxone)

10/2022	Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
11/2017	Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
7/2015	GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
4/2014	Recruitment of participants to a multiple sclerosis trial: the CombiRx experience.
3/2013	Randomized study combining interferon and glatiramer acetate in multiple sclerosis.
11/2009	Glatiramer acetate treatment in PPMS: why males appear to respond favorably.
1/2007	Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
3/2006	Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
1/2006	The use of glatiramer acetate in the treatment of multiple sclerosis.
6/2004	The PROMiSe trial: baseline data review and progress report.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jerry S Wolinsky Research Topics

Disease

46	Multiple Sclerosis 10/2022 - 05/2003
18	Relapsing-Remitting Multiple Sclerosis 01/2022 - 04/2004
13	Chronic Progressive Multiple Sclerosis 10/2021 - 06/2004
8	Infections 01/2021 - 03/2014
7	Disease Progression 12/2020 - 11/2011
4	Inflammation (Inflammations) 12/2019 - 04/2005
3	Atrophy 01/2020 - 04/2005
3	Respiratory Tract Infections (Respiratory Tract Infection) 11/2019 - 10/2014
2	Neoplasms (Cancer) 01/2017 - 01/2017
2	Fatigue 05/2016 - 05/2014
2	Diarrhea 01/2016 - 10/2011
2	Nausea 01/2016 - 10/2011
2	Headache (Headaches) 01/2016 - 03/2014
1	Human Influenza (Influenza) 11/2019
1	Urinary Tract Infections (Urinary Tract Infection) 11/2019
1	Flushing 05/2019
1	Exanthema (Rash) 05/2019
1	Bronchial Spasm 05/2019
1	Pruritus (Itching) 05/2019
1	Leukopenia 01/2018
1	Body Weight (Weight, Body) 01/2018
1	Seizures (Absence Seizure) 01/2018
1	Supraventricular Tachycardia 01/2018
1	Bradycardia 03/2016
1	Basal Cell Carcinoma (Rodent Ulcer) 03/2016
1	Atrioventricular Block 03/2016
1	Lymphopenia (Lymphocytopenia) 03/2016
1	Herpes Zoster 01/2015
1	Cognitive Dysfunction 11/2010
1	Pathologic Processes 06/2002

Drug/Important Bio-Agent (IBA)

14	ocrelizumabIBA 01/2022 - 01/2017
14	teriflunomideIBA 11/2020 - 10/2011
12	Glatiramer Acetate (Copaxone)FDA Link 10/2022 - 08/2003
6	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021 - 01/2015
6	Interferon beta-1a FDA Link 11/2019 - 04/2014
5	InterferonsIBA 01/2021 - 03/2013
5	GadoliniumIBA 01/2020 - 04/2005
5	Immunologic Factors (Immunomodulators)IBA 01/2018 - 09/2014
4	Biomarkers (Surrogate Marker)IBA 12/2019 - 06/2002
3	Alanine Transaminase (SGPT)IBA 01/2016 - 03/2014
2	Natalizumab (Tysabri)FDA Link 01/2021 - 09/2010
2	diroximel fumarateIBA 11/2020 - 01/2020
2	FumaratesIBA 11/2020 - 01/2020
2	Dimethyl FumarateIBA 01/2020 - 01/2019
2	Pharmaceutical PreparationsIBA 03/2014 - 04/2004
2	Protons (Proton)IBA 02/2009 - 06/2004
2	Peptides (Polypeptides)IBA 01/2006 - 04/2004
1	Biotin (Vitamin H)FDA Link 12/2020
1	Contrast MediaIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	insulin receptor-related receptor (IRR)IBA 05/2019
1	Endothelin-1 (Endothelin 1)IBA 01/2019
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2019
1	evobrutinibIBA 01/2019
1	Sphingosine-1-Phosphate ReceptorsIBA 03/2016
1	Complement System Proteins (Complement)IBA 09/2013
1	Rituximab (Mabthera)FDA Link 05/2013
1	Interferon-betaIBA 11/2010

Therapy/Procedure

18	Therapeutics 01/2022 - 05/2003
1	Subcutaneous Injections 07/2015
1	Oral Administration 03/2006